Despite LifeMD's robust revenue growth and optimistic foreca...
Despite LifeMD's robust revenue growth and optimistic forecasts, its P/S ratio aligns with the industry, hinting at shareholder skepticism. If analyst predictions hold true, the stock may be undervalued at present.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000256e0263f3f530.jpg)
免责声明:以上信息不代表Moomoo Technologies Inc.("MTI")的任何立场,不构成与MTI及其关联公司的任何投资建议。
更多信息
评论
登录发表评论